Panacos Pharmaceuticals, Inc.
PANC
$0.00
$0.000.00%
OTC PK
| 09/30/2008 | 06/30/2008 | 03/31/2008 | 12/31/2007 | 09/30/2007 | |
|---|---|---|---|---|---|
| Revenue | 99.00K | 105.00K | 193.00K | 180.00K | 183.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.00K | 105.00K | 193.00K | 180.00K | 183.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 99.00K | 105.00K | 193.00K | 180.00K | 183.00K |
| SG&A Expenses | 11.02M | 12.02M | 12.91M | 12.84M | 12.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.32M | 34.94M | 35.35M | 37.93M | 38.19M |
| Operating Income | -34.22M | -34.84M | -35.16M | -37.75M | -38.01M |
| Income Before Tax | -35.76M | -35.52M | -35.92M | -37.46M | -36.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.76 | -35.52 | -35.92 | -37.46 | -36.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.76M | -35.52M | -35.92M | -37.46M | -36.82M |
| EBIT | -34.22M | -34.84M | -35.16M | -37.75M | -38.01M |
| EBITDA | -33.84M | -34.45M | -34.70M | -37.21M | -37.40M |
| EPS Basic | -0.67 | -0.66 | -0.67 | -0.70 | -0.70 |
| Normalized Basic EPS | -0.42 | -0.41 | -0.41 | -0.42 | -0.42 |
| EPS Diluted | -0.67 | -0.66 | -0.67 | -0.70 | -0.70 |
| Normalized Diluted EPS | -0.42 | -0.41 | -0.41 | -0.42 | -0.42 |
| Average Basic Shares Outstanding | 214.30M | 214.16M | 213.82M | 213.17M | 210.88M |
| Average Diluted Shares Outstanding | 214.30M | 214.16M | 213.82M | 213.17M | 210.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |